Patients with advanced or inoperable Hepatocellular Carcinoma who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH study had similar survival compared to patients who received standard twice-daily systemic treatment with sorafenib, but with less than half the number and significantly fewer severe treatment-related adverse effects and significantly better Quality of Life, according to data presented here at The International Liver Congress 2017.
FDA granted regular approval to Keytruda (pembrolizumab) for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
The NCI Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
New study findings link traveling to an academic medical center for surgical removal of pancreatic or thyroid cancer with higher quality surgical care for both cancers, and longer survival for patients with pancreatic cancer compared with patients who receive treatment at a hospital closer to home.
A study shows that the number of women in the United States living with distant metastatic breast cancer is growing. This is likely due to the aging of the US population and improvements in treatment.
Asterias Biotherapeutics Inc. announced that the results from its completed phase II clinical trial of AST-VAC1 are now available online in Cancer, a leading peer-reviewed journal of the American Cancer Society. The study publication is available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.30696/full.
A study published May 2 in the journal Cancer suggests how both existing and emerging immunotherapy treatments could be successful for sarcomas. Two sarcoma subtypes — leiomyosarcoma and pleomorphic — showed biological characteristics suggesting they are susceptible to an existing immunotherapy approach known as checkpoint inhibitors. This treatment works by blocking a protein that keeps immune cells from attacking cancerous cells.
Two studies by researchers at the Translational Genomics Research Institute and the University of North Carolina Lineberger Comprehensive Cancer Center provide insight on the evolution of glioblastoma and how to potentially combat this most aggressive brain tumor.
In 2017, it is estimated that more than 56,000 new cases of thyroid cancer will be diagnosed in the US—and approximately 75% of those patients will be women.
Array BioPharma announced top-line results from part 2 of the phase III COLUMBUS study evaluating binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor, in patients with BRAF-mutant advanced, unresectable or metastatic melanoma.
